Evidence map›Paper›PMID 42662658›Full record

ArticleACS omega2026

FAP-Inhibitor Homodimers with Engineered Linker-Spacer Units: Toward Optimized Radiopharmaceuticals.

Naveen Kumar, Marcel Martin, Adrianna Bilinska, Elena Menéndez, Ingrid De Meester, Frank Roesch, Axel Rominger, Eleni Gourni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naveen KumarDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Marcel MartinDepartment of ChemistryTRIGA Site, Johannes-Gutenberg University, Mainz 55128, Germany.
Adrianna BilinskaDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Elena MenéndezDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Ingrid De MeesterDepartment of Pharmaceutical Sciences, Laboratory of Medical Biochemistry, University of Antwerp, Wilrijk-Antwerp 2610, Belgium.ORCID https://orcid.org/0000-0002-3421-0124
Frank RoeschDepartment of ChemistryTRIGA Site, Johannes-Gutenberg University, Mainz 55128, Germany.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Eleni GourniDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.ORCID https://orcid.org/0000-0003-2198-382X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monomeric fibroblast activation protein inhibitors (FAPi) based PET tracers have demonstrated very suitable imaging characteristics preclinically in various cancer models. More recently, homodimeric FAP inhibitors (FAPi dimers), that consist of two identical FAPi targeting vectors, have been developed, offering prolonged tumor retention and thus enhancing the potential of targeted radioligand therapy (TRT) with long-lived therapeutic radionuclides such as

Identifiers

PMID42662658
PMCPMC13520045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.